Avadel, Jazz Settle Patent and Antitrust Disputes Over Lumryz

Avadel Pharmaceuticals Plc and Jazz Pharmaceuticals Plc ended yearslong narcolepsy-drug litigation with a global settlement that includes a $90 million Jazz payment, reciprocal patent rights, and new royalty terms for Avadel’s once-nightly Lumryz.

The companies will promptly file stipulations to dismiss patent and antitrust cases in the US District Court for the District of Delaware, according to Jazz’s Tuesday regulatory filing with the US Securities and Exchange Commission and Avadel’s Wednesday statement.

The pact resolves all remaining claims between the companies, including Avadel’s antitrust and contract allegations that had been set for a November jury trial. Jazz denied any ...